Coronary disease & ACSRandomised controlled trial
Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer
- Randomised controlled trial
- open-label
- 4 centres of a single academic institution
Authors' conclusion
In this randomized clinical trial in men with localized PCa treated with radiation plus ADT, the GnRH agonist leuprolide was associated with greater coronary plaque progression within 12 months compared with the GnRH antagonist relugolix.
Study context
- Population
- Men with nonmetastatic prostate cancer without prior androgen deprivation therapy (ADT) receiving pelvic radiotherapy with ADT ≥6 months62 analysed
- Participants
- 65 men
- Comparison
- Gonadotropin-releasing hormone (GnRH) agonist leuprolide vs GnRH antagonist relugolix
- Leuproliden = 31
- Relugolixn = 31reference
- Primary endpoint
- Change in coronary total plaque volume (TPV) by coronary CT angiography
- Follow-up
- 12 months after ADT initiation
Primary result
Change in TPV · 12 months
Estimated difference
+68.9 mm3
95% CI 23.2–114.5
P = 0.02
As reported in the abstract
Secondary outcomes
| Outcome | estimated difference (mm3) (95% CI) | P value |
|---|---|---|
| Change in noncalcified plaque volume (NCPV) · 12 months · adjusted for baseline plaque volume, age, statin use | +64.5 (31.6–97.3) | P = 0.004 |
Change in calcified plaque volume (CPV) and low-attenuation plaque volume (LAPV) · 12 months
- No significant difference between leuprolide and relugolix
Original publication
Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer. JAMA Cardiol. Published 1 May 2026. doi:10.1001/jamacardio.2025.5586
Summarised from the published abstract; every number is checked against it